Bayer AG head of pharmaceuticals research and development Christian Rommel acknowledges that the conglomerate is working its way through a difficult period, but he oversees an R&D pipeline that needs more time to show that the company’s investments in technologies like chemoproteomics and cell and gene therapies will pay off. It’s a big ask for investors who have been waiting a while already for Bayer’s strategy to deliver significant returns.
Bayer’s Pipeline Refresh Focuses On Early Stage Despite Near-Term Growth Needs
Interview With Pharma R&D Head Christian Rommel
The company is struggling to grow revenue, and the biggest of its four key late-stage assets had a setback, but novel technologies are fueling an R&D strategy shift towards high potential programs.
More from Business
• By
Industry lobbied for pharmaceuticals to be exempt from Trump’s sweeping US tariffs and the effort appears to have paid off. J&J, Lilly and Merck & Co. even got shout outs.
• By
With new Phase II data, Edgewise asserted that EDG-7500, a sarcomere modulator, could offer better efficacy and safety than cardiac myosin inhibitors in hypertrophic cardiomyopathy.
• By
Strong sales growth for the German group’s SGLT2 inhibitor in 2024
• By
The latest in a long line of restructuring measures will see Sumitomo Pharma making a stepped sale of its pharma operations in Asia to major Japanese trading house Marubeni.
More from Scrip
• By
Strong sales growth for the German group’s SGLT2 inhibitor in 2024
• By
After a more than three-year hiatus, China's Hengrui has signalled its return to multiregional Phase III trials as it looks to globalize its innovative pipeline. Meanwhile, a number of other Chinese players have announced plans to kick off Phase III trials this year and beyond.
• By
The latest in a long line of restructuring measures will see Sumitomo Pharma making a stepped sale of its pharma operations in Asia to major Japanese trading house Marubeni.